<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515797</url>
  </required_header>
  <id_info>
    <org_study_id>2020P002523</org_study_id>
    <nct_id>NCT04515797</nct_id>
  </id_info>
  <brief_title>QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir</brief_title>
  <acronym>QUICK-CURE</acronym>
  <official_title>QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center study characterizing the experience of administration of 4 weeks of&#xD;
      pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis&#xD;
      C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to determine if the administration of glecaprevir and pibrentasvir&#xD;
      (G/P) for 4 weeks beginning in the immediate peri-transplant period prevents establishment of&#xD;
      HCV infection in HCV negative recipients receiving transplanted kidneys from HCV RNA positive&#xD;
      donors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12</measure>
    <time_frame>12 weeks post-treatment (16 weeks post-transplant)</time_frame>
    <description>Sustained virologic response 12 weeks after completing G/P</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 Year Study Period</time_frame>
    <description>Serious and non-serious adverse events attributed to study drug and/or HCV-viremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA Viral Load</measure>
    <time_frame>Weeks 2 and 4 of Treatment</time_frame>
    <description>Assessment of HCV RNA viral load at on-treatment visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allograft Function</measure>
    <time_frame>1 Year Study Period</time_frame>
    <description>Post-transplant allograft function measured by mean eGFR over study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Death, Graft Failure, Acute Allograft Rejection, Delayed graft function, ALT elevation</measure>
    <time_frame>1 Year Study Period</time_frame>
    <description>The rate of clinical safety outcomes: death, graft failure, acute allograft rejection, delayed graft functions, ALT elevations &gt; 5x ULN</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Kidney Failure</condition>
  <condition>Hepatitis C</condition>
  <condition>Kidney Disease, Chronic</condition>
  <arm_group>
    <arm_group_label>Treatment with Direct Acting Antiviral for HCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 week treatment period with glecaprevir and pibrentasvir (G/P) within 24 hours of transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir and Pibrentasvir</intervention_name>
    <description>4 weeks of treatment starting within 24 hrs of kidney transplant</description>
    <arm_group_label>Treatment with Direct Acting Antiviral for HCV</arm_group_label>
    <other_name>Direct Acting Antiviral HCV Treatment</other_name>
    <other_name>Mavyret</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Recipient)&#xD;
&#xD;
          1. Met MGH Transplant Center criteria and already listed for kidney transplant with stage&#xD;
             5 CKD / ESRD (eGFR &lt;15 ml/min/1.73m2 or on renal replacement therapy)&#xD;
&#xD;
          2. Must agree to birth control. Women must agree to use birth control in accordance with&#xD;
             Mycophenolate Risk Evaluation and Mitigation Strategy and at least one barrier method&#xD;
&#xD;
          3. No evidence of clinically significant liver disease at the time of transplant&#xD;
             readiness as determined by the clinical team&#xD;
&#xD;
          4. Able to sign informed consent&#xD;
&#xD;
        Inclusion Criteria (Deceased Donor)&#xD;
&#xD;
          1. Detectable HCV NAT test&#xD;
&#xD;
          2. KDPI score is less than â‰¤ 0.850&#xD;
&#xD;
          3. Traditional Donor Selection Criteria Met - acceptable for transplantation per usual&#xD;
             evaluation&#xD;
&#xD;
        Exclusion Criteria (Recipient)&#xD;
&#xD;
          1. Pregnant or nursing (lactating) women&#xD;
&#xD;
          2. HBV positivity (Ag or DNA)&#xD;
&#xD;
          3. Any contra-indication to kidney transplantation per MGH transplant center protocol&#xD;
&#xD;
          4. Any signs or symptoms of clinically significant chronic liver disease per transplant&#xD;
             center physician&#xD;
&#xD;
          5. Inability to discontinue any medication with a known drug-drug interaction as listed&#xD;
             in the G/P package insert&#xD;
&#xD;
        Exclusion Criteria (Deceased Donor)&#xD;
&#xD;
          1. Confirmed HIV&#xD;
&#xD;
          2. Confirmed HBV positive (surface antigen or HBV DNA positive)&#xD;
&#xD;
          3. Any standard contra-indication to donation noted in donor (significant malignancy,&#xD;
             unusual infection, kidney anatomical damage or significant pathology)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nahel Elias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nahel Elias, MD</last_name>
    <phone>6177260174</phone>
    <email>Elias.Nahel@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret Thomas</last_name>
    <phone>6176436266</phone>
    <email>mvthomas@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Thomas</last_name>
      <phone>617-643-6266</phone>
      <email>MVTHOMAS@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jenna Gustafson</last_name>
      <phone>6177243836</phone>
      <email>JLGustafson@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nahel Elias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meghan Sise, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Nahel Elias, M.D.</investigator_full_name>
    <investigator_title>Surgical Director, Kidney Transplant</investigator_title>
  </responsible_party>
  <keyword>Kidney Transplant</keyword>
  <keyword>Kidney Failure</keyword>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

